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Canine parvovirus (CPV) is a non-enveloped virus that replicates in the nucleus 
during infection.  While it is known that it uses the cell’s microtubule network to traverse 
the cytoplasm, the route of nuclear entry is unclear.  The nuclear pore complex was 
thought to be used by the virus due to the presence of nuclear localization sequences 
(NLS) in the VP1 protein.  But recent studies in the minute virus of mice (MVM) have 
proposed that it induces breaks in the nuclear envelop before entering the nucleus via 
these breaks.  In this study, Crandell Feline Kidney (CRFK) cells stably transfected with 
GFP-lamin A/C were micro-injected with CPV capsids whose distribution within the 
cells was then detected using fluorescent-labeled antibodies.  The CPV capsids did not 
appear to induce breaks in the nuclear lamin structure of the cells that was observed for 
the MVM. 
 
 
Introduction 
 
In order to replicate and begin a successful infection in the host cell, viruses must 
cross the plasma membrane and enter the host cell.  In the case of most DNA viruses, 
replication occurs in the nucleus where the virus is able to take advantage of cellular 
factors needed for transcription and replication of the viral genome and post-transcription 
processing of viral mRNA.  Hence they must first pass through the cytoplasm in order to 
get to a perinuclear location, and then the genome must somehow cross the nuclear 
membrane to get into the nucleus. 
The cytoplasm of eukaryotic cells is a viscous mixture containing organelles, the 
cytoskeleton and high concentrations of protein, and these combine to restrict free 
diffusion of particles the size of viruses.  In fact, the transport rate by diffusion of a 
particle the size of parvovirus capsids in the cytoplasm is likely about 10μm per hour 
which is about 600 times slower than that in water (1).  This rate would be too slow for 
efficient infection and replication.  Hence it is likely that the cytoplasmic transport of 
viral particles in the host cell is an active process, rather than due to just passive diffusion.   
The cytoskeleton of the cell is made up of microtubules, and the actin and 
intermediate filament networks.  Microtubules are polarized hollow cylindrical filaments 
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that have a slow-growing minus end located at the microtubule organizing center (MTOC) 
and a fast-growing plus end that extends out into the periphery of the cell.  The 
microtubules and their associated molecular motors, dynein and kinesin, are involved in 
the transport of cellular components around the cell (2). 
Despite the fact that all viruses have to transport their genome and associated 
proteins through the cytoplasm during infection, the details of this movement have been 
largely uncharacterized.  Microtubules have been reported to be involved in the 
cytoplasmic transport of many viruses, with the microtubule-associated protein dynein in 
particular playing a role for adenovirus (3) and herpes simplex virus type 1 (HSV-1) (4), 
and suggested to play a role for parvovirus capsids (16). 
After traversing the cytoplasm to a perinuclear location, many viruses enter the 
nucleus by making use of the cell’s nuclear transport machinery.  In particular, they bind 
to soluble cytoplasmic import receptors using the specific nuclear localization signals 
(NLS) on their viral proteins.  This complex of receptor and cargo is then transported into 
the nucleus through the nuclear pore complex (NPC) (5).  But it has been recently 
reported that a parvovirus, the minute virus of mice (MVM), may bypass the NPC route 
by inducing breaks in the nuclear envelope and entering the nucleus via these breaks (6, 
7).  It has also been shown that the viral capsids can pass through the nuclear pore in 
more-or-less intact form in a process that involves the nuclear transport machinery and 
regions of basic amino acids which are found in the unique N-terminal sequence of the 
VP1 protein (8).  These sequences are buried within the capsids of the viruses when they 
are first formed, but are thought to become revealed during the cell entry process (8).   
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The canine parvovirus (CPV) is a member of the Parvoviridae family that causes 
enteritis and myocarditis in canidae (9).  It is a small (26nm diameter), icosahedral, non-
enveloped DNA virus that contains a ~ 5,000 linear, single-stranded genome.  When first 
formed, the virion contains two capsid proteins (VP1 and VP2) with molecular sizes of 
83 and 67kDa respectively (10), and a third VP3 protein is formed in full (DNA 
containing) capsids by proteolytic removal of ~ 19 residues from the N-terminus of VP2 
(11).  The exact function of this cleavage is not known, but the VP2 N-termini of MVM 
capsids contain residues that can be phosphorylated to allow nuclear export of the newly 
formed capsids (12).   
CPV enters the host cell by binding to the transferrin receptor (TfR) on the cell 
surface, leading it into an infectious pathway that starts with clathrin-mediated 
microtubule-dependent endocytosis and the accumulation of viral capsids within 
perinuclear vesicles (13, 14).  While the mechanism by which the capsids escape the 
endosomal vesicles are not known, the activity of a virally-associated phospholipase A2 
in the N-terminal sequence of VP1 appears to be involved (15).  Within the cytoplasm, 
the capsids move towards the nuclear membrane in a process mediated by microtubules, 
as seen from the blockage of nuclear localization in the presence of nocodazole that 
depolymerizes microtubules (16).   
In some previous studies, it was seen that nuclear import of CPV capsids involved 
modifications of viral capsids that exposed sequences resembling classical NLS within 
the N-terminal unique region of the VP1 (17).  In particular, the N-terminal sequence 
(PAKRARRGYK) between residues 4 and 13 mediated nuclear import of a heterologous 
protein, as seen when it was conjugated to bovine serum albumin (BSA) (18), and some 
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specific changes in this basic sequence reduced the relative infectivity of the capsids (17).  
Although the VP1 N-terminus is inaccessible in the native structure of the CPV capsid, it 
can be exposed in vitro without disassembly of the capsid (17).      
In our experiments, we re-examined the cytoplasmic movement of the canine 
parvovirus capsids towards the nucleus using cells that have been stably transfected to 
express green fluorescent protein (GFP)-labeled lamin A/C (19).  The nuclear lamin 
provides a network of intermediate filaments on which the nuclear envelope is erected 
upon.  The objective was to define the effects of the capsids on the nuclear envelope 
integrity which might affect its ability to enter the nucleus, or to enter the nucleus by 
NPC-mediated transport mechanisms.  These studies involved microinjecting purified 
viruses, or control proteins, into cells and then following the distribution of virus or 
protein in the cells.  In some cases the viruses or proteins were linked to nuclear 
localization peptides.  While some of these viruses or proteins were conjugated with 
fluorescent dyes, others were detected by staining using specific antibodies.  In addition, 
we investigated whether the breaks in the nuclear envelope observed in the MVM system 
can be seen in the case of CPV.   
 
Materials and Methods 
 
Cells and viruses: Crandell Feline Kidney (CRFK) cells were grown and maintained in a 
1:1 mixture of McCoy’s 5A medium and Leibovitz L15 medium with 5% fetal calf serum 
at 37ºC with 5% CO2.  In addition, some CRFK cells were transfected with plasmids 
expressing GFP-lamin A/C to label the inner nuclear membrane using Lipofectamine 
(Invitrogen USA) before the transfected cells were selected with 400μg/ml of G418.  
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Prior to microinjection, the cells were grown at 1 × 104 per cm2 on glass cover-slips in 
tissue culture dishes overnight. 
CPV capsids were prepared by growth of the virus in Norden Laboratory feline kidney 
(NLFK) cells, and the capsids were then concentrated by precipitation with polyethylene 
glycol followed by sucrose gradient centrifugation.  Before use in microinjection, the 
virus was washed in microinjection buffer (10mM Tris-HCl-120mM KCl pH7.4), and 
then concentrated to ~ 2μg/ml in a Microcon YM-30 concentrator (Millipore). 
Antibodies and chemicals: In some cases the injected BSA was detected using chicken 
anti-BSA (Genetex) followed by goat anti-chicken conjugated to Cy 3.5 (Abcam) diluted 
in PBS containing 0.15% Triton X-100 and 0.01% sodium azide.  Injected CPV was 
detected using a rabbit antibody against CPV capsids made in Cornell, followed by goat 
anti-rabbit conjugated to Texas Red (Jackson ImmunoResearch) diluted in PBS 
containing 0.15% Triton X-100 and 0.01% sodium azide.   
Rhodamine-labeled BSA with SV-40 large T-antigen NLS was obtained from Sigma 
while unlabeled BSA (Fisher Scientific) was labeled with Alexa 594 dye (Invitrogen).  
Finally the nocodazole used to disrupt the microtubules in the cell was obtained from 
Sigma. 
Microinjection, antibody and drug treatments: The CRFK cells were micro-injected 
with 0.1 – 0.5pl of full (DNA-containing) CPV capsids at ~ 2 mg/ml using Eppendorf 
5171 Micromanipulator and 5246 Microinjector, with the microinjection needles being 
pulled from 1.0mm borosilicate glass capillaries (Harvard Apparatus, Kent UK) with 
Sutter P-97 Flaming/Brown Micropipette Puller.  The viral capsids were concentrated to 
~ 2mg/ml and dialyzed against microinjection buffer.  The cells were then incubated at 
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37ºC for various time intervals between 0 and 4 hours before being fixed with 4% 
paraformaldehyde in phosphate-buffered saline (PBS) for 30 minutes at room 
temperature.  For the directly labeled virus or protein, they were directly detected and 
observed in both live and fixed cells by fluorescent microscopy. 
The viruses were then detected by incubating the cells in the respective antibodies as 
described above.  After a final wash in 1X PBS, the coverslips were mounted on 
microscope slides with Immu-mount (Thermo, Pittsburgh PA).   
In experiments involving nocodazole, the CRFK cells were pre-treated with 20μM of 
nocodazole for 1 hour before micro-injection.  The drug treatment was maintained after 
micro-injection for 4 hours before the cells were fixed and stained as above. 
In the control experiments, the BSA was either directly observed via its fluorescent label 
or stained using antibodies.     
Microscopy and Imaging: The slides were examined using both regular fluorescent 
(Nikon Eclipse TE300 using Nikon Plan Fluor 40X or 60X objectives) and confocal 
fluorescent microscopes (Olympus IX70 with Olympus Fluoview using PlanApo 60X 
objective).  Pictures of the cells were taken using the SimplePCI (Compix Inc., Imaging 
Systems) and Fluoview (Olympus) softwares, and assembled using Adobe Photoshop.   
 
Results 
 
Microtubule-dependent, nucleus directed transport of microinjected viral capsids.  
In order to investigate the transport of cytoplasmic viral capsids to the nucleus, viral 
capsids were injected into cells in the presence and absence of nocodazole.  In the 
absence of nocodazole, the full CPV viral capsids were distributed throughout the 
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cytoplasm of the cell in the form of numerous fluorescent dots (green in Figures 1A and 
1B) that could represent either individual capsids or clusters of capsids immediately after 
microinjection (0hr).  After 4 hours, there appeared to be localization of the viruses to the 
nuclear region in about 30% of the cells (Figure 1B).   
By disrupting the microtubule network using nocodazole treatment that 
depolymerizes the microtubules, there was a reduction in nuclear accumulation of viruses 
(Figure 2), which remained distributed throughout the cytoplasm. 
 
 
 
 
 
   0 hr 
Figure 1A: Intracellular localization of CPV full capsids (green) after microinjection into 
the cytoplasm of CRFK cells (red) after 0 hr 
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 4 hr 
Figure 1B: Intracellular localization of CPV full capsids (green) after microinjection into 
the cytoplasm of CRFK cells (red) after 4 hr. 
 
 
 4 hr 
Figure 2: Intracellular localization of CPV full capsids (green) 4 hr after microinjection 
into the cytoplasm of CRFK cells (red) treated with nocodazole 
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Figure 3: Intracellular localization of BSA-594, BSA-NLS and CPV capsids (red) 1 hour 
after microinjection into the cytoplasm of transfected cells, and structure of the nuclear 
envelope (GFP-Lamin A/C) in the cells (green) 
 
Effect of microinjected viral capsids on nuclear envelope.  Here I used cells 
expressing the nuclear envelope associated protein lamin A/C fused to GFP as a marker 
for the nuclear membrane.  As controls, these GFP-lamin A/C-transfected cells were 
microinjected with BSA labeled with Alexa Fluor 594 Dye (BSA-594) or with 
10 
 
Rhodamine-labeled BSA with SV-40 large T-antigen NLS (BSA-NLS).  The cells were 
then incubated at 37ºC for 1 hour before being fixed with 4% PFA.  The nuclear envelope 
did not appear to have any breaks or changes in structure in both cases as observed from 
the complete oval outline of GFP-lamin in the nucleus of the microinjected cells (Figure 
3).  These transfected CRFK cells were also microinjected with purified full CPV capsids.  
After 1 hour, there was little to no localization of the virus inside the nucleus (Figure 3).  
In addition, there again appeared to be no changes in the lamin A/C structure of the 
nucleus (Figure 3). 
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Discussion 
Passive diffusion of particles the size of viruses is limited by the characteristics of 
the cytoplasm, making it extremely unlikely that macromolecules of that size can move 
within the cell by just diffusion.  Hence efficient transport of viruses in cells would 
require the hijacking of the host transport system.  Previous studies have shown that 
intact microtubules are required during viral infection (14) and the role of these 
microtubules has been associated with transport of viral capsids through the cytoplasm to 
the nucleus using nocodazole treatment (16).  The results presented here have re-affirmed 
the importance of microtubules to cytoplasmic transport of the viral capsids.   
DNA viruses replicate in the nucleus to take advantage of the various host factors 
present there.  To enter the nucleus, many of them have been found to use the nuclear 
pore complexes (NPC).  In particular, parvoviruses are potentially small enough to pass 
through the NPC intact without capsid disassembly or deformation since they are only 18 
– 24nm in diameter (20), well within the 28 – 38nm-diameter upper size limit of cargo 
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that has been found to be able to pass through the NPC (21).  It has previously been 
shown that the MVM capsids can pass through the nuclear pore in more-or-less intact 
form by use of the nuclear transport machinery.  In addition, there are regions of basic 
amino acids in the unique N-terminal sequence of the VP1 protein that play a role in the 
use of classical nuclear pore-dependent nuclear targeting (8).  Although these sequences 
are buried within the viral capsids when they are initially produced, they are thought to 
become exposed during the cell entry process (8).  But recent evidence has offered a 
novel alternative route taken by the MVM to enter the nucleus.  It has been reported that 
the MVM may bypass the NPC route by causing breaks (~ 100 – 200nm) in the nuclear 
envelope, allowing viral particles to enter the nucleus via these breaks by some as yet 
undefined mechanisms (6, 7).   
In the case of the CPV, similar sequences resembling classical NLS within the N-
terminal unique region of the VP1 have been found.  As with MVM, the VP1 N-terminus 
is inaccessible in the native structure of the CPV capsid, it can be exposed in vitro 
without disassembly of the capsid (17).  The results presented here suggest that the CPV 
capsids do not induce the breaks or changes of structure in the nuclear envelope observed 
in the MVM (Figure 3). 
The different results obtained here from those reported for the MVM capsids may 
reflect a difference in the pathways used by the viruses, or differences in the way in 
which experiments are conducted.  In the MVM studies, the mammalian cells were 
permeabilized by treatment with Digitonin, which permeabilizes the plasma membrane 
but in general not the nuclear membrane.  In those studies, the lamin B of the cells was 
detected with an antibody after fixing the cells and incubating them with further 
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detergents to permeabilize the nucleus.  These treatments may therefore have made the 
cells more sensitive to nuclear disruption.  To resolve these differences and further define 
the pathway of nuclear entry, we would need to use alternative approaches combining the 
different methods of exposing the nucleus to the virions, and to do these studies in the 
presence of other control reagents.   
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